

Cardiovascular Drug Delivery

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" published by Humana/Springer (1st ed 2008; 2nd ed 2014, 3rd edn 2019, in preparation). His other recent relevant books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition, Peking University Press 2011, 3rd ed Springer 2017) and "Textbook of Personalized Medicine", (Springer 2009; Japanese edition 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), and "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011).

A B O U T T H I S R E P O R T

The original report on Cardiovascular Drug Delivery appeared as a chapter in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery. Cardiovascular Drug Delivery has now been detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech.

November 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	10
1. Cardiovascular Diseases	12
Introduction	12
History of cardiovascular drug delivery	12
Overview of cardiovascular disease	13
Coronary artery disease.....	13
<i>Angina pectoris.....</i>	<i>13</i>
<i>Myocardial infarction</i>	<i>13</i>
<i>Limitations of current therapies for myocardial ischemic disease</i>	<i>14</i>
Cardiomyopathies	14
Cardiac arrhythmias	14
Congestive heart failure.....	15
Peripheral arterial disease	15
<i>Current management</i>	<i>16</i>
Atherosclerosis	16
The endothelium as a target for cardiovascular therapeutics.....	16
Molecular cardiology.....	16
Cardiogenomics	16
Cardioproteomics.....	17
Personalized cardiology	17
Pharmacogenomics of cardiovascular disorders.....	18
Modifying the genetic risk for myocardial infarction	18
Management of heart failure	19
Management of hypertension	19
<i>Pharmacogenomics of diuretic drugs</i>	<i>20</i>
<i>Pharmacogenomics of ACE inhibitors</i>	<i>20</i>
<i>Management of hypertension by personalized approach.....</i>	<i>20</i>
Pharmacogenetics of lipid-lowering therapies	20
<i>Polymorphisms in genes involved in cholesterol metabolism.....</i>	<i>21</i>
<i>Role of eNOS gene polymorphisms.....</i>	<i>21</i>
Important advances in cardiovascular therapeutics	22
Drug delivery, biotechnology and the cardiovascular system	22
Role of cardiovascular imaging in cardiovascular therapeutics.....	23
Biologic therapeutics for cardiovascular disorders	23
Chronopharmacotherapy of cardiovascular diseases	23
2. Methods for Drug Delivery to the Cardiovascular System	26
Introduction	26
Routes of drug delivery to the cardiovascular system.....	26
Local administration of drugs to the cardiovascular system	26
Intramyocardial drug delivery.....	26
Drug delivery via coronary venous system	27
Intrapericardial drug delivery	27
Formulations for drug delivery to the cardiovascular system	28
Sustained and controlled release.....	28
<i>Programming the release at a defined time</i>	<i>29</i>
<i>Dosage formulation of calcium channel blockers</i>	<i>29</i>
<i>Sustained and controlled release verapamil.....</i>	<i>29</i>
Methods of administration of proteins and peptides	29
<i>Delivery of peptides by subcutaneous injection.....</i>	<i>30</i>
<i>Depot formulations and implants</i>	<i>30</i>
<i>Poly(ethylene glycol) technology.....</i>	<i>30</i>
<i>Liposomes for cardiovascular drug delivery</i>	<i>31</i>
<i>Microencapsulation for protein delivery.....</i>	<i>31</i>
<i>Localized delivery of biomaterials for tissue engineering</i>	<i>31</i>
<i>Oral delivery of proteins and peptides.....</i>	<i>31</i>
Monoclonal antibodies for cardiovascular disorders	33
Abciximab.....	34
Canakinumab	34
PCSK9 MAbs.....	34
DDS to improve systemic delivery of cardiovascular drugs.....	34
Nanotechnology-based drug delivery.....	35
Controlled delivery of nanoparticles to injured vasculature	36
Nanoparticles for cardiovascular imaging and targeted drug delivery	36
Nanofiber-based scaffolds with drug-release properties	37
Targeted drug delivery to the cardiovascular system	37

Immunotargeting of liposomes to activated vascular endothelial cells	38
PEGylated biodegradable particles targeted to inflamed endothelium	38
Devices for cardiovascular drug delivery	39
Local drug delivery by catheters	39
Microneedle for periarterial injection.....	41
Nanotechnology-based devices for the cardiovascular system.....	42
<i>Liposomal nanodevices for targeted cardiovascular drug delivery</i>	42
<i>Nanotechnology approach to the problem of "vulnerable plaque"</i>	42
Drug delivery in the management of cardiovascular disease	43
Drug delivery in the management of hypertension	43
<i>Transnasal drug delivery for hypertension</i>	44
<i>Transdermal drug delivery for hypertension</i>	44
<i>Oral extended and controlled release preparations for hypertension</i>	44
<i>Long-acting hypertensives for 24 h blood pressure control</i>	45
<i>Drug delivery to control early morning blood pressure peak</i>	45
<i>Role of drug delivery in improving compliance with antihypertensive therapy</i>	46
<i>Vaccines for hypertension</i>	46
Drug delivery in the treatment of angina pectoris.....	47
<i>Sustained and controlled-release nitrate for angina pectoris</i>	47
<i>Transdermal nitrate therapy</i>	47
<i>Controlled release calcium blockers for angina pectoris</i>	48
<i>Sustained-release formulation of ranolazine</i>	49
DDS in the management of ischemic heart disease	49
<i>Intravenous emulsified formulations of halogenated anesthetics</i>	50
<i>Injectable peptide nanofibers for myocardial ischemia</i>	50
<i>Delivery of angiogenesis-inducing agents for myocardial ischemia</i>	50
Drug delivery for myocardial infarction	51
Drug delivery for cardioprotection	52
<i>Cardioprotection during reperfusion</i>	54
Drug delivery for congestive heart failure.....	55
<i>Oral human brain-type natriuretic peptide</i>	55
<i>Nitric oxide-based therapies for congestive heart failure</i>	55
<i>Automated drug delivery system for cardiac failure</i>	55
Drug delivery for cardiac rhythm disorders.....	56
Drug delivery in the management of pulmonary hypertension	56
<i>Endothelin receptor antagonist treatment of PAH</i>	57
<i>Prostacyclin by inhalation</i>	57
<i>Treprostinil</i>	57
Anticoagulation in cardiovascular disease.....	57
<i>Oral heparin</i>	58
<i>Low molecular weight heparin-loaded polymeric nanoparticles</i>	58
<i>Transdermal anticoagulants</i>	58
Thrombolysis for cardiovascular disorders	59
<i>Use of ultrasound to facilitate thrombolysis</i>	59
<i>Delivery of alteplase through the AngioJet rheolytic catheter</i>	59
Drug delivery for peripheral arterial disease	59
<i>Delivery of thrombolytic agent to the clot through a catheter</i>	60
<i>Delivery of growth factors to promote angiogenesis in ischemic limbs</i>	60
<i>Immune modulation therapy for PAD</i>	60
<i>NO-based therapies for peripheral arterial disease</i>	61
Drug delivery in the management of hypercholesterolemia.....	61
<i>Controlled/sustained release formulations of statins</i>	61
<i>Combinations of statins with other drugs to increase efficacy</i>	62
<i>Controlled release fenofibrate</i>	63
<i>Extended release nicotinic acid</i>	63
<i>Intravenous infusion of lipoprotein preparations to raise HDL</i>	64
<i>Innovative approaches to hypercholesterolemia</i>	65
<i>Therapeutic antagonism of ANGPTL3 gene</i>	65
<i>Vaccines for lowering cholesterol by targeting PCSK9</i>	67
Single dose therapy for more than one cardiovascular disorder.....	67
3. Cell Therapy for Cardiovascular Disorders	68
Introduction	68
Inducing the proliferation of cardiomyocytes	68
Role of stem cells in repair of the heart.....	68
Cell-mediated immune modulation for chronic heart disease	68
Cell therapy for atherosclerotic coronary artery disease	69
Transplantation of myoblasts for myocardial infarction.....	69
<i>MyoCell™ (Bioheart)</i>	70
Transplantation of cardiac progenitor cells for revascularization of myocardium	71
Methods of delivery of cells to the heart	71

Cellular cardiomyoplasty	71
IGF-1 delivery by nanofibers to improve cell therapy for MI.....	72
Intracoronary infusion of bone marrow-derived cells for AMI	72
Non-invasive delivery of cells to the heart by Morph@guide catheter.....	72
Transplantation of stem cells for myocardial infarction.....	73
<i>Transplantation of embryonic stem cells</i>	73
<i>Transplantation of hematopoietic stem cells</i>	73
<i>Transplantation of cord blood stem cells for myocardial infarction</i>	73
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	74
<i>Human mesenchymal stem cells for cardiac regeneration</i>	74
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i>	75
<i>Transplantation of expanded adult SCs derived from the heart</i>	75
<i>Transplantation of endothelial cells</i>	75
Transplantation of genetically modified cells	76
<i>Transplantation of cells secreting vascular endothelial growth factor</i>	76
<i>Transplantation of genetically modified bone marrow stem cells</i>	76
Cell transplantation for congestive heart failure	76
<i>Injection of adult stem cells for congestive heart failure</i>	76
<i>Intracoronary infusion of cardiac stem cells</i>	77
<i>Myoblasts for treatment of congestive heart failure</i>	77
Role of cell therapy in cardiac arrhythmias	77
<i>Atrioventricular conduction block</i>	78
<i>Ventricular tachycardia</i>	78
<i>ESCs for correction of congenital heart defects</i>	79
Cardiac progenitor cells for treatment of heart disease in children	79
Stem cell therapy for peripheral arterial disease	80
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	80
Clinical trials of cell therapy in cardiovascular disease.....	80
A critical evaluation of cell therapy for heart disease	83
Publications of clinical trials of cell therapy for CVD	83
Future directions for cell therapy of CVD	83
Prospects of adult stem cell therapy for repair of heart	84
Regeneration of cardiomyocytes without use of cardiac stem cells.....	85
Repair of the damaged heart	85
4. Gene Therapy for Cardiovascular Disorders	88
Introduction	88
Techniques of gene transfer to the cardiovascular system	89
Direct plasmid injection into the myocardium	89
Catheter-based systems for vector delivery	89
Ultrasound microbubbles for cardiovascular gene delivery	90
Vectors for cardiovascular gene therapy	90
<i>AAV vectors for therapeutic delivery to the heart</i>	90
<i>Adenoviral vectors for cardiovascular diseases</i>	91
<i>Plasmid DNA-based delivery in cardiovascular disorders</i>	91
Hypoxia-regulated gene therapy for myocardial ischemia	91
Angiogenesis and gene therapy of ischemic disorders	92
Therapeutic angiogenesis vs. vascular growth factor therapy	93
Gene painting for delivery of targeted gene therapy to the heart	93
Gene delivery to vascular endothelium	93
<i>Overexpression of eNOS to improve vasodilation with Ad vectors</i>	93
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	94
Gene therapy for genetic cardiovascular disorders	94
Genetic disorders predisposing to atherosclerosis.....	94
Familial hypercholesterolemia.....	95
Apolipoprotein E deficiency.....	96
Hypertension.....	96
Genetic factors for myocardial infarction	97
Acquired cardiovascular diseases	97
Coronary artery disease with angina pectoris.....	97
<i>Ad5FGF-4</i>	97
Ischemic heart disease with myocardial infarction	98
<i>Angiogenesis for cardiovascular disease</i>	99
<i>Myocardial repair with IGF-1 therapy</i>	99
<i>miRNA gene therapy for ischemic heart disease</i>	100
Congestive heart failure	100
<i>Rationale of gene therapy in CHF</i>	100
<i>AAV-mediated gene transfer for CHF</i>	101
<i>AngioCell gene therapy for CHF</i>	101
<i>β-ARKct gene therapy</i>	101
<i>Elevating cardiac dATP by gene therapy to improve cardiac function</i>	102

<i>Intracoronary adenovirus-mediated gene therapy for CHF</i>	103
<i>nNOS gene transfer in CHF</i>	103
Gene therapy for cardiac arrhythmias.....	103
<i>Gene transfer for biological pacemakers</i>	104
<i>Management of arrhythmias due to myoblast transplantation</i>	104
<i>Genetically engineered cells as biological pacemakers</i>	105
Cholesterol reduction by genetic engineering of PCSK9 gene.....	105
Gene therapy and heart transplantation.....	106
Gene therapy for peripheral arterial disease.....	106
<i>Angiogenesis by gene therapy</i>	106
<i>HIF-1α gene therapy for peripheral arterial disease</i>	106
<i>HGF gene therapy for peripheral arterial disease</i>	107
<i>Ischemic neuropathy secondary to peripheral arterial disease</i>	107
Maintaining vascular patency after surgery.....	108
Antisense therapy for cardiovascular disorders.....	108
Antisense therapy for hypertension.....	109
Antisense therapy for hypercholesterolemia.....	109
<i>Mipomersen</i>	109
<i>Antisense oligonucleotides targeting ANGPTL3</i>	110
<i>Antisense drugs targeting PCSK9</i>	110
RNAi for cardiovascular disorders.....	110
RNAi for hypercholesterolemia.....	111
<i>siRNAs targeting PCSK9</i>	111
microRNA and the cardiovascular system.....	111
<i>Role of miRNAs in angiogenesis</i>	112
<i>Role of miRNAs in cardiac hypertrophy and failure</i>	112
<i>Role of miRNAs in conduction and rhythm disorders of the heart</i>	113
<i>miRNA-based approach for reduction of hypercholesterolemia</i>	113
<i>miRNAs as therapeutic targets for cardiovascular diseases</i>	113
<i>Future prospects of miRNA in the cardiovascular therapeutics</i>	114
Future prospects of gene therapy of cardiovascular disorders.....	114
Companies involved in gene therapy of cardiovascular disorders.....	115
5. Drug-Eluting Stents.....	116
Introduction.....	116
Percutaneous transluminal coronary angioplasty.....	116
Stents.....	116
Restenosis.....	116
Pathomechanism.....	117
Treatment.....	117
Nitric oxide-based therapies for restenosis.....	118
Carbon monoxide inhalation for preventing restenosis.....	118
Antisense approaches for prevention of restenosis after angioplasty.....	119
Gene therapy to prevent restenosis after angioplasty.....	119
<i>Delivery of gene therapy for restenosis</i>	119
<i>HSV-1 gene therapy to prevent intimal hyperplasia</i>	119
<i>miRNA-based gene therapy for restenosis following angioplasty</i>	120
<i>Nonviral gene therapy to prevent intimal hyperplasia</i>	120
<i>NOS gene therapy for restenosis</i>	120
<i>Targets for gene therapy of restenosis</i>	121
<i>Viral vector-mediated gene therapy for restenosis</i>	122
Drug delivery devices for restenosis.....	123
Local drug delivery by catheter.....	123
Stenosis associated with stents.....	124
Absorbable metal stents.....	124
Drug-eluting stents.....	124
Various types of DES.....	125
<i>CYPHER$\text{\textcircled{R}}$ sirolimus-eluting coronary stent</i>	125
<i>Dexamethasone-eluting stents</i>	125
<i>NO-generating stents</i>	126
<i>Paclitaxel-eluting stents</i>	126
<i>Sirolimus-eluting vs paclitaxel-eluting stents</i>	127
Novel technologies for DES.....	127
<i>Bio-absorbable DES</i>	127
<i>Drug-eluting stents coated with polymer surfaces</i>	128
<i>Endeavour DES</i>	128
<i>Polymer-free drug-coated stent for patients at high risk of bleeding</i>	129
<i>Stents for delivery of gene therapy</i>	130
<i>Stem cell-based stents</i>	130
<i>VAN 10-4 DES</i>	131
Nanotechnology-based stents.....	131

<i>Drugs encapsulated in biodegradable nanoparticles</i>	131
<i>Magnetic nanoparticle-coated DES</i>	131
<i>Magnetic nanoparticles encapsulating paclitaxel targeted to stents</i>	133
<i>Nanocoated DES</i>	133
<i>Nanopores to enhance compatibility of DES</i>	134
<i>Paclitaxel-encapsulated targeted lipid-polymeric nanoparticles</i>	134
The ideal DES.....	134
Companies developing drug-eluting stents	135
Clinical trials of drug-eluting stents	136
<i>Measurements used in clinical trials of DES</i>	136
<i>TAXUS paclitaxel-eluting stents</i>	136
<i>XIENCE™ V everolimus-eluting coronary stent</i>	137
<i>COSTAR II clinical trial</i>	138
<i>Endeavor RESOLUTE zotarolimus-eluting stent system</i>	138
<i>CUSTOM I clinical trial</i>	139
<i>NOBORI CORE Trial</i>	139
<i>LEADERS trial</i>	140
<i>Comparison of DES releasing either zotarolimus or everolimus</i>	140
Comparison of DES versus bare metal stents in clinical trials.....	140
<i>Biosorbable vs drug-eluting metallic stents</i>	143
<i>Multi-Link Vision bare metal stent vs DES</i>	144
<i>Guidelines for DES vs BMS</i>	144
<i>DES vs BMS for off-label indications</i>	144
<i>Role of DES in cases of bare-metal in-stent restenosis</i>	145
Comparison of revascularization methods for stable coronary disease.....	145
<i>DES versus coronary artery bypass graft</i>	145
<i>DES versus balloon catheter coated with paclitaxel</i>	146
<i>DES versus intracoronary radiation therapy for recurrent stenosis</i>	146
<i>PCI plus DES as the preferred method for treatment of MI</i>	147
Cost-effectiveness of DES	147
Safety issues of DES	148
<i>Adverse reactions to DES</i>	148
<i>Long-term safety studies of DES</i>	149
<i>Endothelial vascular dysfunction due to sirolimus</i>	150
<i>Risk of clotting with DES</i>	150
<i>Effect of blood clot on release of drug from DES</i>	151
Measures to prevent clotting associated with DES	152
<i>Clopidogrel use and long-term outcomes of patients receiving DES</i>	152
<i>Cangrelor for platelet inhibition to prevent stent thrombosis</i>	152
<i>Prasugrel as antiplatelet agent</i>	152
<i>Use of magnetized cell lining to prevent clotting of DES</i>	153
Regulatory issues of DES	153
Approved drug-eluting stents	153
Safety issues of drug-eluting stents.....	154
Assessment of efficacy of various drug-eluting stents.....	155
Future prospects of treatment of restenosis by DES	155
Effect of stent cost on clinical applications	155
Future role of DES in the management of cardiovascular diseases.....	156
Improvements in stent technology	156
<i>Bioabsorbable stent</i>	157
DES vs drug-eluting balloons.....	157
6. Markets for Cardiovascular Drug Delivery.....	158
Introduction	158
Epidemiology of cardiovascular disease.....	158
Cost of care of cardiovascular disorders	159
Cardiovascular markets according to important diseases	160
Antithrombotics	160
Anticholesterol agents	160
Antihypertensive agents	161
Drugs for congestive heart failure	161
Markets for innovative technologies for cardiovascular disorders	161
Markets for cell therapy of cardiovascular disorders.....	161
Markets for gene therapy of cardiovascular disorders	162
Markets for drug-eluting stents.....	162
<i>Major players in DES market</i>	162
<i>Impact of safety issues on future markets for DES</i>	162
<i>DES market in Asia</i>	163
<i>Patenting and legal issues of DES</i>	164
<i>The financial impact of DES on cardiovascular markets</i>	164
Unmet needs for cardiovascular drug delivery.....	165

Role of DDS in developing cardiovascular markets	165
Markets for cardiovascular devices	166
Marketing of innovative cardiovascular drug delivery devices.....	166
Direct to consumer advertising of DES.....	166
Future trends in the integration of drug delivery with therapeutics	167
Future of cardiovascular drug delivery	167
7. Companies involved in Cardiovascular Drug Delivery	168
Profiles of companies.....	168
Collaborations.....	255
8. References.....	258

Tables

Table 1-1: Landmarks in the historical evolution of cardiovascular drug delivery	12
Table 1-2: Approaches to management of myocardial infarction and its sequelae	13
Table 1-3: Gene polymorphisms that alter cardiovascular response to drugs	18
Table 2-1: Routes of drug delivery used for treatment of cardiovascular disorders	26
Table 2-2: Formulations for drug delivery to the cardiovascular system	28
Table 2-3: Monoclonal antibodies used for cardiovascular disorders	33
Table 2-4: Improved methods of systemic drug delivery of cardiovascular drugs	35
Table 2-5: Targeted delivery of therapeutic substances to the cardiovascular system	38
Table 2-6: Classification of devices for drug delivery to the cardiovascular system	39
Table 2-7: Various methods of delivery of therapeutic agents for hypertension.....	43
Table 2-8: Marketed controlled/ extended release preparation for hypertension.....	45
Table 2-9: Methods of delivery of nitrate therapy in angina pectoris.....	47
Table 2-10: Drug delivery in ischemic heart disease.....	49
Table 2-11: Strategies for cardioprotection	52
Table 2-12: Drug delivery for peripheral arterial disorders	60
Table 3-1: Clinical trials of cell therapy in cardiovascular disease	80
Table 4-1: Cardiovascular disorders for which gene therapy is being considered.	88
Table 4-2: Catheter-based systems for vector delivery to the cardiovascular system.....	89
Table 4-3: Potential applications of antisense in cardiovascular disorders.....	109
Table 4-4: Companies involved in gene therapy of cardiovascular diseases	115
Table 5-1: Treatment of restenosis	117
Table 5-2: Devices used for drug delivery in restenosis	123
Table 5-3: Companies involved in drug-eluting stents	135
Table 5-4: Drug-eluting stents approved by the FDA	153
Table 6-1: Prevalence of cardiovascular disorders in major markets: US 2017-2027	159
Table 6-2: Prevalence of cardiovascular disorders in major markets: Europe 2017-2027.....	159
Table 6-3: Prevalence of cardiovascular disorders in major markets: Japan 2017-2027	159
Table 6-4: Values of cardiovascular DDS in major markets 2017-2027	160
Table 6-5: Markets for innovative technologies for cardiovascular disorders 2017-2027.....	161
Table 7-1: Top 5 companies in cardiovascular drug delivery	168
Table 7-2: Collaborations in cardiovascular drug delivery.....	255

Figures

Figure 1-1: Drug delivery, biotechnology and cardiovascular diseases	22
Figure 2-1: MicroSyringe for periarterial injection	41
Figure 2-2: Patch for delivery of follistatin-like 1 factor for myocardial infarction	52
Figure 2-3: Lipoprotein metabolism in ANGPTL3 deficiency	66
Figure 5-1: Vicious circle of vascular occlusion following angioplasty and stenting.....	118
Figure 5-2: Measurement of in-stent stenosis.....	124
Figure 5-3: Medtronic's Endeavour drug-eluting stent.....	129
Figure 5-4: Magnetic nanoparticle-coated stent	133
Figure 6-1: Unmet needs for cardiovascular drug delivery.....	165